A study to evaluate the efficacy of omalizumab in patients with severe allergic asthama and overlapping chronic-obstructive-pulmonary-disease (COPD): An Australasian Xolair Registry (AXR) study

Trial Profile

A study to evaluate the efficacy of omalizumab in patients with severe allergic asthama and overlapping chronic-obstructive-pulmonary-disease (COPD): An Australasian Xolair Registry (AXR) study

Completed
Phase of Trial: Phase IV

Latest Information Update: 05 Nov 2016

At a glance

  • Drugs Omalizumab (Primary)
  • Indications Allergic asthma; Chronic obstructive pulmonary disease
  • Focus Therapeutic Use
  • Most Recent Events

    • 05 Nov 2016 New trial record
    • 11 Oct 2016 Results published in the Chest
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top